Orphan drugs in Europe

被引：0
|
作者：
Emma Dorey
机构：
来源：
Nature Biotechnology | 1999年 / 17卷 / 8期
关键词：
D O I：
10.1038/11639
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：737 / 737
相关论文
共 50 条
  • [1] Orphan drugs BioMarin Europe replies
    Quartel, Adrian
    Lennertz, James
    BRITISH MEDICAL JOURNAL, 2010, 341
  • [2] INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE
    Qiu, T.
    Hanna, E.
    Chachoua, L.
    Dussart, C.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S461 - S462
  • [3] THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE
    Nixon, F.
    VALUE IN HEALTH, 2008, 11 (06) : A375 - A376
  • [4] Orphan drugs Authors' reply to BioMarin Europe
    Nicholl, David J.
    Hilton-Jones, David
    Palace, Jacqueline
    Winer, John
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
  • [5] Orphan Drugs: Underrated Opportunities for The Developers in Europe
    Tillet, Yves
    Maillols-Perroy, Anne-Catherine
    THERAPIE, 2015, 70 (04): : 351 - 357
  • [6] Access to orphan drugs in Europe: current and future issues
    Michel, Morgane
    Toumi, Mondher
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (01) : 23 - 29
  • [7] EUROPE-CHINA COMPARISON OF ORPHAN DRUGS APPROVALS
    Qiu, T.
    Hanna, E.
    Ma, F.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S110 - S111
  • [8] ORPHAN DRUGS: HEALTH TECHNOLOGY ASSESSMENT AND PRICING IN EUROPE
    Jaroslawski, S.
    Toumi, M.
    Korchagina, D.
    Jadot, G.
    VALUE IN HEALTH, 2018, 21 : S24 - S24
  • [9] COMPARISON OF ORPHAN DRUGS PRICES BETWEEN EUROPE AND JAPAN
    Belgaied, W.
    Hanna, E.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S110 - S110
  • [10] Neglected tropical diseases in Europe: rare diseases and orphan drugs?
    Calleri, Guido
    Angheben, Andrea
    Albonico, Marco
    INFECTION, 2019, 47 (01) : 3 - 5
12345